Quanterix (QTRX) COO gains stock via RSU vesting with tax withholding
Quanterix Corp's Chief Operating Officer, Michael Francis Miller, converted 229 restricted stock units into common shares on March 31, 2026. To cover tax obligations, 69 shares were withheld at $3.52 per share, resulting in a net increase of 160 common shares. Following these transactions, Miller directly holds 31,431 shares of Quanterix common stock.
Quanterix Corp (QTRX) Stock Price Quote Today & Current Price Chart | Capital.com Australia
Capital.com Australia provides a stock price quote and current price chart for Quanterix Corp (QTRX). The platform offers online trading services through its smart investment app.
Quanterix Corp (QTRX) Stock Price Quote Today & Current Price Chart
This article provides a current stock price quote and chart for Quanterix Corp (QTRX), highlighting its intraday performance, key stats, and trading conditions on Capital.com. It details CFD trading information, including spreads, overnight funding adjustments, and margin requirements. The page also includes related share articles for other companies and customer reviews for the trading platform.
Quanterix Corp (QTRX) Stock Price Quote Today & Current Price Chart
This article provides the current stock price and chart for Quanterix Corp (QTRX), along with key trading conditions and financial statistics. It highlights QTRX's current price of 3.75, an increase of 9.97%, and details CFD trading information such as spread, overnight funding adjustments, and margin requirements. The page also includes related share articles and customer reviews for the Capital.com platform.
Quanterix Corp (QTRX) Stock Price Quote Today & Current Price Chart
The article provides a title for Quanterix Corp (QTRX) stock price quote and current price chart, indicating financial information. It also mentions "Online Trading with Smart Investment App" from Capital.com, suggesting a trading platform context.
Quanterix Corporation Schedules 2026 Annual Meeting of Stockholders for June 15
Quanterix Corporation has announced that its 2026 Annual Meeting of Stockholders will be held on June 15, 2026. The announcement was made on March 27, 2026, and the meeting will cover corporate matters and provide updates on the company's performance and future plans. Quanterix is known for its high-definition biomarker detection technology and regularly engages with stakeholders through these meetings.
Quanterix moves annual meeting date, sets April 6 proposal deadline
Quanterix Corporation has announced that its 2026 annual meeting will be held virtually on June 9, 2026, at 10:00 am ET. Due to the advancement of the meeting date, the deadline for shareholder proposals submitted under Rule 14a-8 and other proposals or director nominations has been set for April 6, 2026. Stockholders of record as of April 14, 2026, will be eligible to vote.
Vanguard disaggregates holdings after realignment; QTRX stake now reported by subsidiaries (QTRX)
The Vanguard Group amended its Schedule 13G/A, reporting zero beneficial ownership of Quanterix Corp (QTRX) common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538. The filing indicates a reporting change rather than an economic sale, with future disclosures expected from the individual subsidiaries.
Quanterix Corp Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today
This article provides a detailed analysis of Quanterix Corp (QTRX) stock, including its live price ($3.58 as of March 27, 2026), key financial metrics like market cap ($183.07 M) and revenue ($138.90 M), and historical performance returns. It also includes analyst ratings, investment options for US stocks, and frequently asked questions about the company.
Quanterix (QTRX) CLO Daniel Char granted RSUs and stock options
Quanterix Corp's Chief Legal Officer, Daniel Char, has reported initial equity holdings, including 33,962 restricted stock units and 113,171 stock options, granted on January 15, 2026. Both awards will vest 25% on the first anniversary of the grant date, with the remainder vesting in 36 equal monthly installments, creating a multi-year incentive structure. The stock options have an exercise price of $7.95 per share, and the grants were recorded in an SEC Form 3 filing.
Quanterix targets $169M–$174M 2026 revenue with focus on diagnostics and cost synergies
Quanterix aims to achieve revenue between $169 million and $174 million by 2026, driven by growth in its diagnostics segment and strategic cost-cutting measures. The company is focusing on leveraging its Simoa technology to expand its clinical diagnostics footprint. This financial projection reflects a commitment to operational efficiency and market expansion.
Quanterix (QTRX) COO Miller details PSUs, RSUs, options and shares in Form 3
Quanterix COO Michael Francis Miller filed an initial ownership report (Form 3) detailing his equity holdings in the company as of February 23, 2026. The report indicates he holds Performance Stock Units (PSUs), various Restricted Stock Unit (RSU) awards, stock options with differing exercise prices and expiration dates, and directly owned shares of Common Stock. This filing provides transparency on his existing equity interests but does not reflect new transactions.
Quanterix (QTRX) COO gains shares from RSU vesting as stock withheld for taxes
Quanterix Corp.'s Chief Operating Officer, Michael Francis Miller, received common stock from restricted stock unit (RSU) vesting on March 15, 2026. A total of 1,558 shares were exercised, and 549 shares were withheld at $4.72 per share to cover tax obligations. Following these routine transactions, Miller directly holds 31,271 shares of Quanterix common stock.
Invenomic Capital Management LP Grows Stake in Quanterix Corporation $QTRX
Invenomic Capital Management LP significantly increased its stake in Quanterix Corporation (NASDAQ: QTRX) by 21.7% in Q3, now holding 1,393,005 shares valued at $7.56 million. Other institutional investors like Balyasny Asset Management and Portolan Capital Management also boosted their positions, resulting in 86.48% institutional ownership. Despite this increased investor interest, Quanterix reported an EPS miss for the quarter, negative margins, and has a consensus "Hold" rating from analysts with an average price target of $11.33.
Portolan Capital Management LLC Buys 626,229 Shares of Quanterix Corporation $QTRX
Portolan Capital Management LLC significantly increased its stake in Quanterix Corporation (NASDAQ:QTRX) by 17.2%, acquiring an additional 626,229 shares, bringing its total to 4,259,851 shares, representing about 9.12% of the company. Other institutional investors also added to their holdings, with institutional ownership of Quanterix now at 86.48%. Despite missing EPS estimates in its last quarterly report, Quanterix's revenue beat expectations and analysts currently rate the stock as a "Hold" with an average target price of $11.33.
Quanterix and Akoya amend merger deal
The article states that Quanterix and Akoya have amended their merger deal. However, no further details about the changes or the original terms are provided in the current content. Additional information is needed to understand the implications of this amendment for both companies.
William Blair Investment Management LLC Increases Holdings in Quanterix Corporation $QTRX
William Blair Investment Management LLC has increased its stake in Quanterix Corporation (NASDAQ:QTRX) by 16.6%, acquiring an additional 187,299 shares to bring its total holdings to 1,315,280 shares, valued at approximately $7.14 million. Despite this increase in institutional ownership, Quanterix recently reported a quarterly EPS miss of ($0.38) and a negative return on equity, with analysts projecting a full-year EPS of -0.98. The stock opened at $5.87, down about 7.3%, and currently holds a consensus "Hold" rating from Wall Street with an average price target of $11.33.
Neurocode Launches Groundbreaking pTau217 Blood Test for Alzheimer's Disease Clinical Diagnosis
Neurocode USA, Inc. has launched ALZpath Dx, an innovative blood test for Alzheimer's disease (AD) that measures circulating levels of pTau217. This test is the first of its kind available for clinical diagnostic use in the U.S., offering accuracy comparable to brain imaging or CSF testing but with greater accessibility, lower cost, and less invasiveness. The ALZpath Dx test, powered by Quanterix Simoa technology, marks a significant advancement in early and accurate AD diagnosis, patient stratification for clinical trials, and treatment monitoring.
Quanterix Corporation (NASDAQ:QTRX) Q4 2025 Earnings Call Transcript
Quanterix Corporation discussed its Q4 2025 earnings, reporting $43.9 million in total revenue, a 25% increase year-over-year. The company highlighted strong performance in its base business, progress with its Alzheimer's diagnostic test (LucentAD complete), and a focus on achieving cash flow breakeven in 2026. New CEO Everett Cunningham outlined strategic priorities including leveraging differentiated technologies in neurology, oncology, and immunology, and expanding into the diagnostics market.
Quanterix (QTRX) Revenue Growth Keeps Losses Central To Bulls’ Long-Term Narrative
Quanterix (QTRX) reported Q4 FY 2025 revenue of US$43.9 million and a basic EPS loss of US$0.49, with full-year revenue of US$138.9 million and a basic EPS loss of US$2.51, highlighting significant revenue growth alongside ongoing losses. The company's trailing losses have widened over five years, and it is not expected to achieve profitability in the next three years, challenging the bullish narrative that relies on future execution and growth in proteomics. Despite a lower price-to-sales multiple compared to peers, risks such as shareholder dilution and stock volatility persist.
Quanterix (QTRX) grows Q4 revenue, deepens 2025 loss, eyes 2026 cash breakeven
Quanterix (QTRX) reported increased Q4 2025 revenue of $43.9 million but a full-year 2025 net loss of $107.2 million, significantly wider than the previous year due to lower gross margins and higher operating expenses. The company aims for cash flow breakeven in the second half of 2026, driven by $74 million in cost synergies from the Akoya acquisition and advancements in its Alzheimer's diagnostics. Quanterix ended 2025 with $121.6 million in cash and forecasts 2026 revenue between $169 million and $174 million.
Quanterix Corporation 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:QTRX) 2026-03-03
This article provides details about Quanterix Corporation's (NASDAQ: QTRX) Q4 2025 earnings call presentation. The slide deck for the earnings call was published on March 3, 2026, and is available for investors. The content was sourced from SA Transcripts, which covers thousands of quarterly earnings calls.
Quanterix Corp reports results for the quarter ended December 31 - Earnings Summary
Quanterix Corp (QTRX) has reported its financial results for the quarter that ended on December 31. This earnings summary provides a concise overview of the company's performance during this period. The report was compiled by Refinitiv and distributed via Reuters.
Quanterix Corporation 8-K Filing Analysis
Quanterix Corporation has announced its financial results for the fourth quarter and full year ending December 31, 2025, showing a 25% revenue increase in Q4 but a widening Adjusted EBITDA loss. The company achieved key milestones in its Alzheimer’s Diagnostics business, including an FDA 510(k) submission and a Medicare reimbursement rate for its LucentAD Complete test. Quanterix projects revenue between $169 million and $174 million for 2026 and expects to achieve cash flow breakeven in the second half of the year.
Alzheimer’s blood test heads to 15,000 community events a year
Lucent Diagnostics (a Quanterix brand) has partnered with Life Line Screening to offer its non-invasive blood-based biomarker test for Alzheimer's disease identification nationwide, with programs currently in Florida, California, and Texas. This collaboration aims to expand access to early detection in community settings like senior centers and churches. Life Line Screening hosts over 15,000 community events annually, providing a scalable infrastructure to reach a wide population.
Earnings Outlook For Quanterix
Quanterix (NASDAQ: QTRX) is set to release its quarterly earnings on March 2, 2026, with analysts expecting an EPS of $-0.40. The company's stock price dropped after beating EPS estimates last quarter, and shares are down 7.69% over the last 52 weeks. Quanterix, a life sciences company specializing in ultra-sensitive digital immunoassay platforms, shows positive revenue growth but struggles with return on assets, while maintaining a prudent debt-to-equity ratio.
Quanterix Corp expected to post a loss of 45 cents a share - Earnings Preview
Quanterix Corp (QTRX) is projected to report an earnings loss of 45 cents per share, according to this earnings preview. The article details this financial forecast from Refinitiv.
Envestnet Asset Management Inc. Grows Holdings in Quanterix Corporation $QTRX
Envestnet Asset Management Inc. significantly increased its stake in Quanterix Corporation (NASDAQ:QTRX) by 122.7% in the third quarter of 2025, bringing its total holdings to 515,861 shares, valued at approximately $2.8 million. Other institutional investors also adjusted their positions, and 86.48% of Quanterix stock is now owned by institutional investors and hedge funds. Analyst ratings for Quanterix are mixed, with a consensus "Hold" rating and a target price of $11.33, while the company's stock trades at $6.29 with a negative P/E ratio.
Biomarker firm Quanterix plans two March investor webcasts
Quanterix Corporation (Nasdaq: QTRX) announced that its executive leadership team would participate in two investor conferences in March 2026: the 46th Annual TD Cowen Healthcare Conference on March 4th and the Leerink Global Healthcare Conference 2026 on March 9th. The company, a leader in ultra-sensitive biomarker detection, will engage in fireside chats and one-on-one meetings, with webcasts available for interested parties. This follows their recent acquisition of Akoya Biosciences and advancements in Alzheimer's disease detection.
Quanterix (QTRX) Expected to Announce Quarterly Earnings on Monday
Quanterix (QTRX) is anticipated to release its Q4 2025 earnings after market close on Monday, March 2nd, with analysts forecasting a loss of ($0.27) per share on revenues of $37.95 million. The stock closed at $5.67, with a market cap of $264.85 million, and analysts currently hold a "Hold" consensus rating with a target price of $11.33. Institutional investors own approximately 86.48% of Quanterix shares.
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer’s Blood Test
Quanterix Corp has submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test designed to aid in Alzheimer’s disease detection. This test, which previously received Breakthrough Device Designation, uses proprietary Simoa technology to measure five key analytes to identify amyloid brain plaques in patients with cognitive symptoms. The company aims for the test to become a gold standard in clinical diagnostics, bridging the gap between early detection and new disease-modifying therapies.
Investors can hear Quanterix 2025 results discussed on Mar. 2 call
Quanterix Corporation (Nasdaq: QTRX) announced it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T. to discuss its fourth quarter and full-year 2025 financial results. A press release detailing these results will be issued prior to the call, after market close on the same day. Investors can access the live conference call via phone or webcast, with an archived replay available for one year.
Quanterix submits FDA 510(k) for multi-analyte Alzheimer's blood test
Quanterix has submitted a 510(k) premarket notification to the FDA for its Lucent Diagnostics pTau-217 and Aβ42/40 Ratio Test. This multi-analyte blood test is intended to aid in the diagnosis of Alzheimer's disease and represents a significant step towards more accessible diagnostic tools for the condition. The submission marks a critical milestone for Quanterix in advancing its neurological diagnostic platform.
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
Quanterix (QTRX) has submitted a 510(k) premarket notification to the FDA for its multi-analyte algorithmic blood test for Alzheimer's disease diagnosis. The test, which uses Quanterix's Simoa technology, measures five Alzheimer's-related biomarkers and previously received FDA Breakthrough Device Designation. This submission is a significant step towards positioning the technology as a clinical diagnostic standard and could expand the company's addressable market for non-invasive Alzheimer's diagnostics.
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
Quanterix has submitted a 510(k) premarket notification to the FDA for its multi-analyte algorithmic blood test for Alzheimer's disease, marking a significant step in offering non-invasive diagnostic solutions. The test, built on the company's Simoa technology, measures five Alzheimer's-related biomarkers and received Breakthrough Device Designation. This submission positions Quanterix to become a standard in clinical diagnostics for early Alzheimer's identification.
Quanterix announces FDA 510(k) submission for a multi-analyte algorithmic blood test for Alzheimer’s disease detection
Quanterix has submitted a 510(k) application to the FDA for a multi-analyte algorithmic blood test designed for Alzheimer's disease detection. This submission, dated February 3, 2026, highlights the company's continuous efforts in advancing precision health diagnostics through its ultra-sensitive digital immunoassay platforms.
Quanterix (QTRX) Submits Alzheimer's Blood Test for FDA Approval
Quanterix (QTRX) has submitted a 510(k) premarket notification to the FDA for its innovative Alzheimer's blood test, which uses a multi-analyte algorithmic approach and Simoa technology to help diagnose the disease in patients with cognitive symptoms. Despite this significant step in early detection, the company faces financial challenges, including a negative operating margin, a potentially distressing Altman Z-Score, and high stock volatility. Investors are advised to consider both the opportunities presented by the technology and the associated financial and operational risks.
Quanterix submits FDA 510(k) for multi-analyte Alzheimer’s blood test
Quanterix Corporation has submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test designed to identify amyloid brain plaques in patients with cognitive symptoms, a key indicator of Alzheimer's disease. The test utilizes the company's Simoa technology to measure five biomarkers associated with amyloid pathology, tau pathology, neuroinflammation, and axonal damage. This submission is supported by extensive clinical evidence and marks a significant step towards establishing the technology as a standard in clinical diagnostics for early Alzheimer's detection.
Blood test to spot Alzheimer’s earlier moves to FDA review
Quanterix Corporation has submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test designed for early Alzheimer's disease detection. This test, previously granted Breakthrough Device Designation, aims to identify amyloid brain plaques using a panel of five biomarkers and Quanterix's Simoa technology. The company believes this non-invasive, comprehensive approach will improve diagnostic clarity for patients with cognitive symptoms, especially in early disease stages.
15-year brain study: blood test combo better flags Alzheimer’s risk
Quanterix Corporation announced a landmark study published in JAMA Network Open, demonstrating that combining multiple blood-based biomarkers offers a significantly more comprehensive and accurate assessment of Alzheimer's risk and progression compared to individual markers. The 15-year study, led by Amsterdam UMC, utilized Quanterix's Simoa ultra-sensitive technology to measure biomarkers for amyloid, tau, neuroinflammation, and neurodegeneration. These findings support Quanterix's multi-analyte laboratory developed tests, like LucentAD Complete, for personalized Alzheimer's risk assessment and clinical trial enrollment.
The Truth About Quanterix Corp (QTRX): Tiny Biotech, Massive Hype – But Is It Worth Your Money?
Quanterix Corp (QTRX) is a biotech company specializing in ultra-sensitive biomarker detection for early disease detection, particularly in neurology and inflammatory diseases. While not mainstream viral, it's gaining attention in specialized financial and medical tech communities due to its potential as a game-changer. Investors should be aware of its high-volatility, high-risk profile, making it suitable for long-term, research-heavy investors comfortable with biotech market swings rather than those seeking stable cash flow.
The Truth About Quanterix Corp (QTRX): Tiny Biotech, Massive Hype – But Is It Worth Your Money?
Quanterix Corp (QTRX) is a biotech company specializing in ultra-sensitive blood tests for early disease detection, particularly in neurology and inflammatory conditions. While it's gaining traction among specialist investors and researchers due to its innovative Simoa technology and platform-plus-assays model, it remains a high-risk, high-upside speculative play. Investors should be aware of its volatility and competitive landscape against larger diagnostic companies, weighing its strong technology against the need for scaled, profitable adoption.
Quanterix (QTRX) Price Target Increased by 11.54% to 7.40
The average one-year price target for Quanterix (QTRX) has been increased by 11.54% to $7.40 per share, up from $6.63. This target is an average of analyst estimates, with a range from $6.06 to $8.40. The current target represents a 3.35% increase from the latest closing price of $7.16.
Quanterix gains on CEO change, revenue guidance (update)
This article is a placeholder with no content. It specifies a title indicating Quanterix's stock gains due to a CEO change and revenue guidance, and also includes metadata about publication and crawl times. However, no actual article text was provided to summarize.
Quanterix (NASDAQ: QTRX) appoints Everett Cunningham as CEO and director
Quanterix Corporation (NASDAQ: QTRX) has announced a significant leadership transition, appointing Everett Cunningham as its new President and CEO, effective January 19, 2026. This follows Masoud Toloue, Ph.D.'s departure under a separation agreement. Cunningham's compensation package includes a $750,000 annual base salary, performance-based bonuses, a $600,000 sign-on payment, and substantial equity awards tied to both time-based vesting and stock price hurdles, signaling a focus on performance-driven incentives.
Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)
Quanterix Corporation (NASDAQ:QTRX) currently has a price-to-sales (P/S) ratio of 2.9x, which is lower than the Life Sciences industry average in the United States, prompting a look into why. Despite a recent decline in revenue, analysts forecast a strong 17% annual revenue growth over the next three years, significantly outperforming the industry's projected 6.5% growth. This disparity between strong future growth forecasts and a low P/S ratio suggests that shareholders may be doubtful of the forecasts or that the market is pricing in significant risks.
Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)
Quanterix Corporation's (NASDAQ:QTRX) current price-to-sales (P/S) ratio of 2.9x is lower than the industry average, despite analyst forecasts predicting strong revenue growth of 17% per year over the next three years, compared to the industry's 6.5%. This discrepancy suggests that investors are hesitant about the company's future, possibly due to past revenue declines and perceived risks, even though the company's long-term growth prospects appear favorable. The article highlights that while future growth is projected positively, the market's current sentiment keeps the P/S ratio low.
Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)
Quanterix Corporation (NASDAQ:QTRX) has a price-to-sales (P/S) ratio of 2.9x, which is lower than many peers in the Life Sciences industry. This low P/S ratio is likely due to the company's recent declining revenue, despite future analyst forecasts predicting strong revenue growth of 17% per year, significantly outpacing the industry average. The market appears to be skeptical of these positive forecasts, leading to a depressed P/S ratio.
Canaccord Genuity reiterates Hold rating on Quanterix stock
Canaccord Genuity has reiterated its Hold rating and $8.00 price target for Quanterix Corp. (NASDAQ:QTRX), citing a potential 23% upside. The firm acknowledges the appointment of Everett Cunningham as the new President and CEO, seeing his background as a strong fit, but remains cautious awaiting clarity on his priorities and consistent operational execution due to the company's significant cash burn. Quanterix's Q3 2025 revenue exceeded forecasts, but EPS missed expectations, while the company continues to contribute to medical research with its biomarker technology.
Canaccord Genuity reiterates Hold rating on Quanterix stock By Investing.com
Canaccord Genuity has reiterated a Hold rating and an $8.00 price target for Quanterix Corp. (NASDAQ:QTRX), indicating a potential 23% upside. The company recently appointed Everett Cunningham as its new President and CEO, effective January 19, 2026. Despite a positive view on the new CEO's background, Canaccord Genuity remains cautious, awaiting clarity on his priorities and consistent operational execution, especially given Quanterix's cash burn and revenue decline, although it maintains strong liquidity.
